BioProcess Blog

BioProcess Blog |

Subscribe to our RSS Feed

Cell Culture World Congress USA 2014

Monday Sep 1, 2014

Join BPTC at Terrapinn’s Cell Culture World Congress USA conference, co-located with the HPAPI Congress, in Boston, MA from September 15-16.  We look forward to mingling with fellow cell culture experts to discuss process enhancements, innovative technologies, and bottle-neck reduction opportunities. Please come visit us at booth 13 to learn how we can help improve your upstream process and accelerate your development programs.

Share

2014 BioProcess International Conference & Exhibition

Friday Aug 29, 2014

Join BPTC at IBC’s 11th Annual BioProcess International Conference & Exhibition in Boston, MA from October 20-23, 2014. In addition to exhibiting at the conference (booth #810), BPTC consultants will be actively participating in a number of sessions.  Susan Dana Jones, Vice President and Principal Consultant, will be leading a panel discussion on “Identifying and Integrating Critical Early Development Activities to Enable Successful Progression from Discovery to First-in-Human Clinical Trials” on October 22 at 4:30PM. Susan will also be leading a course titled, “Introduction to BioPharmaceutical Development and Manufacturing” with Sheila Magil, Senior Consultant.  This course will provide an overview of the technical considerations and activities required to progress a biopharmaceutical from discovery through early process development and manufacturing. If you still haven’t registered, take advantage of our discount code, BP14SKRE3, for 20% off the standard rates. See you there! For more information, visit: http://bit.ly/1zVjTJt.

Share

Has the time come to embrace continuous processing?

Tuesday Aug 26, 2014

By: Howard Levine  (hlevineatbptcdotcom)   and Frank Riske  (friskeatbptdotcom)  

As in years past, the Recovery of Biological Products XVI Meeting in Rostock, Germany (July 27‑31) provided a forum for lively debate on new technologies for downstream processing, new applications of old technology, and glimpses of what the future of our industry might hold. High among the topics of interest at the conference was continuous processing as a replacement for traditional batch processing of monoclonal antibodies and other recombinant proteins. Jon Coffman (Boehringer Ingelheim) began the conference pointing out that the cost of manufacturing per se is not limiting our ability to deliver products at a cost effective level but rather the high failure rate of products in clinical trials and the time required for overall product development were more critical in driving the cost of medicines today. Jon then showed how continuous processing might help accelerate production of material for clinical trials, allowing companies to shorten overall timelines to commercialization. This was followed by a presentation from Charlie Cooney (MIT) in which he reviewed the evolution of continuous processing for traditional pharmaceuticals and argued that the biopharmaceutical industry can also benefit from the efficiencies and flexibility continuous processing can provide.

Later in the program, Veena Warikoo (Genzyme), Oliver Kaltenbrunner (Amgen), and Alex Xenopoulos (Merck Millipore) presented their views on the development and implementation of integrated, fully continuous processes for recombinant proteins and monoclonal antibodies. While there was discussion and some disagreement over implementation of “end to end” continuous processes, these presentations and several posters at the meeting, did make the case for the use of continuous perfusion cell culture and continuous chromatography for initial product capture for recombinant proteins that are relatively unstable (e.g. Factor VIII) and helped define the objectives for implementing continuous processing for more stable products such as monoclonal antibodies. In these cases, continuous processing, whether for a single unit operation such as Protein A capture or a more fully integrated end-to-end process, there may be economic and/or productivity gains to be had through continuous (or semi-continuous) processing. Furthermore, advances in process analytical technology (PAT) may also favor using aspects of continuous downstream processing. With FDA and most industry experts embracing the concept of continuous processing, it is likely that some level of continuous processing will become commonplace in biopharmaceutical industry in the near future. Looking toward this future, Karol Lacki (GE Healthcare) gave an excellent presentation on a unified approach to process development that supports batch, semi-, and fully continuous processing without a need to repeat costly process development and process characterization studies should a switch be made from one operational mode to another later on.

The case for sticking with batch processing was made in comments by Brian Kelley (Genentech). According to Brian, conventional batch processes can be economical and suitable for production of biopharmaceuticals, even if very large columns or multiple cycles per column are required to process increasing levels of product in the harvest from large volume bioreactors. For a company like Genentech, with a large base of installed capacity and manufacturing assets, perhaps this is true. However, as companies look toward designing and building “factories of the future,” smaller facilities incorporating some aspects of continuous (perfusion) cell culture and continuous chromatography may be more cost effective and productive than larger facilities built around traditional batch processing. In conclusion, a company decision to use aspects of continuous processing may well depend on the stability of the protein, and an economic and risk analysis of placing such technology into an existing facility, or planned new construction.

Share

CHIs 6th Annual BioProcessing Summit

Monday Aug 4, 2014

Drs. Susan Dana Jones and Sheila Magil will be leading a 1.5-day training course titled, “Introduction to Bioprocessing” from August 18-19, 2014 at the Renaissance Waterfront Hotel in Boston, MA, to be held in conjunction with CHI’s Bioprocessing Summit (running August 18-22). This training seminar offers a comprehensive survey of the steps needed to produce today’s complex biopharmaceuticals from early development through commercial.  The seminar begins with a brief introduction to biologic drugs and the aspects of protein science that drive the intricate progression of analytical and process steps that follows.  We then step through the stages of bioprocessing, beginning with the development of cell lines and ending at the packaging of a finished drug product.  The seminar also will explore emerging process technologies, facility design considerations and the regulatory and quality standards that govern our industry throughout development. The important roles played by the analytical and formulation in developing and gaining approval for a biopharmaceutical are also examined. This 1.5-day class is directed to attendees working in any aspect of industry, including scientific, technical, business, marketing or support functions, who would benefit from receiving a detailed overview of this field. For more information and to register for this seminar, please click here. Interested in learning more about BPTC’s CMC consulting expertise? Please email Julie Adam  (jadamatbptcdotcom)   to pre-arrange a meeting at the conference.

Share

BIO International Convention

Friday Jun 6, 2014

BPTC is pleased to be exhibiting at the 2014 Biotechnology Industry Organization’s International Convention to be held in sunny San Diego, CA from June 23-26.  We hope you’ll take some time to visit us at Booth 1214 in the Bioprocessing Zone to learn more about our extensive biopharmaceutical product development and manufacturing expertise and to enter our daily raffle to win two hours of free consulting. To pre-arrange a meeting to discuss your specific needs, please email Julie Adam  (jadamatbptcdotcom)  . We look forward to seeing you in CA.

Share